ReviewNanomedicine (London, England)2025
Regulating nanomedicines: challenges, opportunities, and the path forward.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Gold and silver nanoparticles for safe and effective biomedical applications.Discover nano · 2026Review
- Phytogenic Nanoparticles for Parkinson's Disease Therapy: Mechanistic Insights, Brain-Targeted Delivery and Neuroprotective Potential.Molecular neurobiology · 2026Review
- The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success.Biology · 2026Review
- Bridging the Gap: Harnessing Phytochemical-Loaded Nanocarriers for Enhanced Epilepsy Treatment.Molecular neurobiology · 2026Review
- Nanoparticulate and Hydrogel Vehicles for Stimuli-Responsive and Sustained Controlled Release of Active Pharmaceutical Ingredients.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Molecular and environmental drivers of antimicrobial resistance: global epidemiology, resistome dynamics, and one health strategies.Archives of microbiology · 2026Review
- Nano-warfare in the oral cavity: antimicrobial strategies and mechanisms in nanodentistry.Odontology · 2026Review
- Nanomaterial toxicity and risk assessment integrating functionalization strategies advanced in vitro models and regulatory perspectives.Discover nano · 2026Review
- Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine.Journal of nanobiotechnology · 2026Review
- Nanomedicine in Cardiovascular Inflammation: Novel Diagnostic and Therapeutic Strategies.Journal of personalized medicine · 2026Review
- Nanotechnology based topical drug delivery systems for psoriasis addressing current strategies clinical progress and manufacturing challenges.Discover nano · 2026Review
- Nanotherapeutics to Overcome Chemotherapy Resistance in Ovarian Cancer.Pharmaceutical research · 2026Review
- Erectile dysfunction and Peyronie's disease: from biologics to nanomedicine-enabled therapies.Sexual medicine · 2026Review
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Lab-on-a-Chip and Microfluidics Technologies for Nano Drug Delivery.Bioengineering (Basel, Switzerland) · 2026Review
- Stimuli-Responsive Carbon Nanotubes for On-Demand Cancer Therapy: A Review.AAPS PharmSciTech · 2026Review
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, nanomedicines have witnessed significant advancements, with various nanocarriers being introduced into clinical practice. Despite this progress, the absence of a well-defined regulatory framework presents major challenges for stakeholders in the pharmaceutical and healthcare industries. Challenges in biocompatibility, nanotoxicology, and regulatory oversight limit the clinical translation of nanomedicines. This review discusses the key challenges and emphasizes on the lack of clear and effective regulations in nanotechnology, which creates obstacles for manufacturers while also leaving legislators, medical practitioners, and the general public unable to properly assess the risk and safety measures associated with the nanomedicines. This review highlights the existing regulatory gaps by analyzing the clinical applications of nanomedicine, discussing the significance of regulatory frameworks. The barriers to the regulatory systems of various countries are compared to identify the multifaceted challenges associated with ensuring the safety and efficacy of nanomedicine interventions. The lack of consensus not only impedes the research and development (R&D) efforts in nanoparticle-based therapies but also affects the future adoption of nanomedicines. There is an urgent need to establish and implement a coherent and globally synchronized regulatory framework to facilitate the innovation and advancements of nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.